Prosecution Insights
Last updated: April 19, 2026

National Institute Of Biological Sciences Beijing

5 pending office actions

Portfolio Summary

5
Total Pending OAs
2
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18270808 A BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 GODDARD, LAURA B 1642 Non-Final OA Jul 03, 2023
17935400 ANTIBODIES AGAINST AREG AND ITS USE MIDDLETON, DANAYA L 1674 Non-Final OA Sep 26, 2022
17813157 SPECIFIC HOST FACTOR OF HEPATITIS B VIRUS INFECTION, AND USE THEREOF ZOU, NIANXIANG 1671 Non-Final OA Jul 18, 2022
17614673 DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS VIJAYARAGHAVAN, JAGAMYA NMN 1633 Final Rejection Nov 29, 2021
17614737 ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE DHAR, MATASHA 1632 Final Rejection Nov 29, 2021

Managing National Institute Of Biological Sciences Beijing's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month